Key facts
- OncoHealth (Atlanta)’s last known valuation is $103.0M (May 2020).
- It has raised $56.5M; the latest was PE Growth/Expansion in Jun 2025.
- Notable investors include Valeo Ventures, Arsenal Capital Partners, Cobalt Ventures (Private Equity), McKesson, The Cigna Group Ventures (Bloomfield).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for OncoHealth (Atlanta)
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoHealth (Atlanta) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoHealth (Atlanta)
Developer of healthcare utilization management technology designed to help manage the total cost of cancer care. The company's technology offers access to current, evidence-based, disease-specific insights on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, thereby enabling healthcare organizations to provide their patients with the ability to achieve reliable outcomes through affordable and optimal treatment.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2009
- Employees
- 211
- Website
- oncohealth.us/
- Ownership
- Privately Held (backing)
OncoHealth (Atlanta) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoHealth (Atlanta) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoHealth (Atlanta) in its N-PORT filings yet. We sweep new filings monthly.